Mori Keiichiro, Miura Noriyoshi, Comperat Eva, Nikles Sven, Pang Karl H, Misrai Vincent, Gomez Rivas Juan, Papalia Rocco, Shariat Shahrokh F, Esperto Francesco, Pradere Benjamin
Department of Urology, Medical University of Vienna, Vienna, Austria -
Department of Urology, The Jikei University School of Medicine, Tokyo, Japan -
Minerva Urol Nephrol. 2021 Feb;73(1):42-49. doi: 10.23736/S2724-6051.20.03778-9. Epub 2020 May 20.
This systematic review and meta-analysis was conducted to assess the prognostic differences between different Gleason patterns in patients with prostate cancer (PC) within Internal Society of Urological Pathology (ISUP) grade group 4 (GG 4).
PUBMED and Scopus databases were searched for articles published prior to December 2019 according to the Preferred Reporting Items for Systematic Review and Meta-analysis statement. Studies were deemed eligible if they compared overall survival (OS), cancer-specific survival (CSS), and surgical pathological outcomes in PC patients categorized as ISUP GG 4 (Gleason Score [GS] 4+4 vs. GS 3+5 or GS 5+3). Formal meta-analyses were performed for these outcomes.
Ten studies with 42,041 patients were eligible for the systematic review and eight studies with 36,250 patients for meta-analysis. The treatment type of included study was three surgery and three radiotherapy. The other four studies included many kinds of treatments such as surgery, radiotherapy, androgen deprivation therapy, and chemotherapy. GS 4+4 was significantly associated with better OS (pooled hazard ratio (HR): 0.52, 95% confidential interval (CI): 0.29-0.91) than GS 3+5 or GS 5+3. Positive surgical margin rates were significantly lower with GS 4+4 than GS 3+5 and GS 5+3 (odds ratio [OR] 0.70/95% CI 0.64-0.77 and OR 0.70/95% CI 0.56-0.87, respectively). In contrast, different Gleason patterns in ISUP GG 4 were not significantly associated with CSS (pooled HR: 0.77, 95% CI: 0.56-1.06).
GS 4+4 in patients with PC was associated with better OS and positive surgical margin rates. It seems likely that there is heterogeneity within ISUP GG 4. However, caution should be exercised in interpreting the conclusions drawn from this study, given the limitations of the study, which include the heterogeneity of the population of interest and the retrospective nature of the primary data evaluated.
本系统评价和荟萃分析旨在评估国际泌尿病理学会(ISUP)4级(GG 4)前列腺癌(PC)患者不同Gleason模式之间的预后差异。
根据系统评价和荟萃分析报告规范,检索了PUBMED和Scopus数据库中2019年12月之前发表的文章。如果研究比较了归类为ISUP GG 4(Gleason评分[GS]4+4与GS 3+5或GS 5+3)的PC患者的总生存期(OS)、癌症特异性生存期(CSS)和手术病理结果,则这些研究被视为合格。对这些结果进行了正式的荟萃分析。
10项研究共42,041例患者符合系统评价标准,8项研究共36,250例患者符合荟萃分析标准。纳入研究的治疗类型包括3项手术和3项放疗。其他4项研究包括多种治疗方法,如手术、放疗、雄激素剥夺治疗和化疗。与GS 3+5或GS 5+3相比,GS 4+4与更好的OS显著相关(合并风险比[HR]:0.52,95%置信区间[CI]:0.29-0.91)。GS 4+4的阳性手术切缘率显著低于GS 3+5和GS 5+3(优势比[OR]分别为0.70/95%CI 0.64-0.77和OR 0.70/95%CI 0.56-0.87)。相比之下,ISUP GG 4中不同的Gleason模式与CSS无显著相关性(合并HR:0.77,95%CI:0.56-1.06)。
PC患者的GS 4+4与更好的OS和阳性手术切缘率相关。ISUP GG 4内部似乎存在异质性。然而,鉴于本研究的局限性,包括研究对象人群的异质性和所评估的原始数据的回顾性性质,在解释本研究得出的结论时应谨慎。